Gastric Cancer

Cards (12)

  • Risk factors for gastric cancer
    • Old age - 70yrs
    • Male - x2 more likely
    • H. Pylori - 60% of cases
    • Gastritis
    • Smoking
    • Alcohol
    • Obesity
    • Diet - pickled/cured/processed foods
    • Family History - 10% of cases
    • Pernicious anaemia
  • What is HDGC?
    • Autosomal dominant gene mutation that increases risk of the more severe diffuse gastric cancer
    • CDH-1 gene mutation which encodes E-cadherin, cells become less cohesive promoting cancer development
    • 50% chance of passing it on increasing gastric cancer risk to 70-80% at aged 80
    • Also increases risk for lobular breast cancer to 40%
  • Gastric cancer is the 6th most common cancer worldwide
  • The most common location of gastric cancer is the pyloric antrum followed by the lesser curvature, cardia, fundus and body of the stomach
  • Signs and symptoms of gastric cancer can include
    • Weight loss
    • Fatigue
    • Bleeding - haematemesis or melena or anaemia
    • Nausea and vomiting
    • Dyspepsia
    • Bloating
    • Dysphagia if cancer affects cardia of stomach
  • Troisier's sign aka Virchow's node
    • A palpable left supraclavicular lymph node
    • Indicates abdominal malignancy
  • Gold standard diagnostic test for gastric cancer is endoscopy with biopsy
  • CT scans are used to asses TNM stage 0-4, which involves
    1. Tumour size and local tissue involvement
    2. Lymph Node involvement
    3. Metastasis
  • 5 year survival for gastric cancer is 30%, improves to 90% if caught in the earliest stage
  • Gastric cancer is managed with
    1. Endoscopic mucosal resection in early stage
    2. Partial/total gastrectomy in late stage
    3. Chemotherapy
    4. Immunotherapy
  • Adjuvant chemotherapy is given after surgery to prevent recurrence
    Neoadjuvant chemotherapy is given before surgery to shrink or stop the spread of cancer
  • Immunotherapy options for gastric cancer:
    Trastuzumab - a HER2 inhibitor, 25% of gastric cancer cases are HER2 positive
    Nivolumab - a monocloncal antibody that inhibits PD1 receptor, increasing antitumor response